HemoGenyx Pharmaceuticals Plc (HEMO) AI Stock Analysis

• Market Cap: £44.46M
• Dividend Yield: N/A
• Average Volume (3M): 113.41K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.76
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.42
• Shares Outstanding: 6,041,255
• 10 Day Avg. Volume: 30,447
• 30 Day Avg. Volume: 113,406
• PEG Ratio: 0.08
• Price to Book (P/B): 14.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: 725.00p ▲(27.64% Upside)

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

Positive Factors

Targeted hematology and immune‑cell platform

A focused R&D platform in hematology and immune‑cell applications targets structural, high‑unmet-need markets (blood disorders, oncology). Platform technologies can generate multiple programs and partnership opportunities, creating durable optionality if clinical progress continues.

Improving operating cash burn

Year‑over‑year reduction in operating cash outflow reflects tangible progress on cost control or program prioritization. Sustained burn improvement lengthens runway, reducing immediate financing pressure and giving management more time to advance programs or seek partner deals.

Lean operating footprint

A small headcount signals a low fixed-cost base typical of early-stage biotech, enabling capital efficiency and outsourcing of expensive activities. This lean structure helps preserve cash, extend runway, and pivot R&D focus without large structural overhead.

Negative Factors

No revenue across 2020–2024

Absence of any revenue over multiple years means no commercial validation and full reliance on external capital to fund operations. This weakens the firm’s ability to self‑fund development or scale, increasing execution risk and exposure to funding cycles.

Deteriorating balance sheet and high leverage

Sharp equity erosion and elevated leverage materially increase solvency risk. High debt relative to equity limits strategic flexibility, raises refinancing and covenant risk, and makes the company more vulnerable to dilution or distress financing over the medium term.

Persistent negative free cash flow and financing dependence

Continued negative free cash flow necessitates recurrent capital raises or debt, which can dilute shareholders or increase interest burdens. That dependence constrains long‑term planning, slows progress on multiple programs, and elevates execution risk for clinical development.

HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model

Company Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

How the Company Makes Money

HemoGenyx Pharmaceuticals Plc Financial Statement Overview

Summary

Financials are very weak: no revenue reported across 2020–2024, ongoing sizable losses, and continued cash burn. While 2024 losses and operating/free cash outflow improved versus 2023, equity fell sharply (~0.9m vs ~2.8m) and leverage increased (debt-to-equity ~2.9x), elevating balance-sheet risk and reliance on external funding.

Income Statement

The income statement remains very weak: the company reported zero revenue across 2020–2024, while losses are persistent and sizable. Net loss improved in 2024 versus 2023 (from about -6.7m to -5.6m), but profitability is still deeply negative and the lack of revenue traction limits visibility on a path to sustainable earnings.

Balance Sheet

Balance sheet risk has increased materially. Equity declined sharply to ~0.9m in 2024 (from ~2.8m in 2023), while debt remains meaningful (~2.6m), pushing leverage higher (debt-to-equity ~2.9x in 2024 vs ~1.0x in 2022–2023). Total assets have also trended down since 2021, and returns on equity are strongly negative, reflecting ongoing capital erosion.

Cash Flow

Cash flow is negative but shows some improvement: operating cash burn narrowed in 2024 to ~-4.1m from ~-6.1m in 2023, and free cash flow also improved to ~-4.1m from ~-6.2m. However, the business still consumes significant cash each year and free cash flow remains firmly negative, implying continued dependence on financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-631.38K	-639.28K	-645.68K	-2.60M	-283.65K	-350.72K
EBITDA	-6.94M	-4.71M	-5.73M	-3.42M	-2.39M	-1.96M
Net Income	-7.81M	-5.62M	-6.69M	-3.98M	-5.10M	-2.08M
Balance Sheet
Total Assets	3.10M	4.21M	6.11M	7.09M	8.52M	2.66M
Cash, Cash Equivalents and Short-Term Investments	226.73K	159.26K	1.25M	2.53M	6.84M	1.81M
Total Debt	2.20M	2.62M	2.95M	3.42M	10.15K	1.63M
Total Liabilities	3.65M	3.36M	3.32M	3.85M	352.84K	1.79M
Stockholders Equity	-500.15K	897.51K	2.82M	3.28M	8.19M	890.84K
Cash Flow
Free Cash Flow	-5.58M	-4.13M	-6.22M	-3.34M	-3.45M	-1.97M
Operating Cash Flow	-5.57M	-4.12M	-6.11M	-2.91M	-2.63M	-1.80M
Investing Cash Flow	235.15K	-24.90K	-31.94K	-420.25K	-938.95K	-169.68K
Financing Cash Flow	1.91M	3.08M	4.45M	-110.14K	8.78M	3.21M

HemoGenyx Pharmaceuticals Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HVO	73 Outperform	£41.22M	7.69	―	2.94%	11.92%	-33.76%
AREC	56 Neutral	£30.77M	-3.69	-204.29%	―	3.31%	21.91%
APTA	52 Neutral	£23.60M	-6.25	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£30.68M	-3.86	-46.84%	―	―	―
HEMO	47 Neutral	£44.46M	-3.32	-609.30%	―	―	―
IMM	46 Neutral	£31.97M	-7.15	-259.88%	―	―	―

HemoGenyx Pharmaceuticals Plc Corporate Events

Hemogenyx Confirms Updated Share Capital and Voting Rights

Hemogenyx Pharmaceuticals has confirmed that its total issued share capital as of 30 January 2026 comprises 6,041,255 ordinary shares of 1p each, with none held in treasury, giving the company an equal number of voting rights. This updated share count provides the key denominator for investors to assess and report any holdings or changes in their interests under UK disclosure and transparency rules, ensuring clarity around the company’s capital structure and regulatory compliance for shareholders and market participants.

The most recent analyst rating on (GB:HEMO) stock is a Sell with a £760.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Hemogenyx Sets Early January Date for Admission of New Shares

Hemogenyx Pharmaceuticals has confirmed that the UK Financial Conduct Authority has scheduled an admission hearing for its new ordinary shares on 5 January 2026, with trading in the new shares expected to commence at around 8:00 a.m. on 6 January 2026. The timing update indicates the capital-related process is progressing as planned, with all other terms from the company’s 18 December 2025 announcement remaining unchanged, providing investors and other stakeholders with clarity on the anticipated schedule for the shares’ admission to trading.

Hemogenyx Pharmaceuticals Announces Equity Issuance and Operational Updates

Hemogenyx Pharmaceuticals plc has issued 123,377 new ordinary shares following warrant exercises, restricted stock unit vesting, and obligations under a Deed of Variation. This issuance, raising £190,000 and leading to adjustments in total issued shares and voting rights, reflects the company’s ongoing efforts to fund operational developments and ensure alignment with regulatory requirements, which may strengthen its market positioning and reassure stakeholders.

Hemogenyx Pharmaceuticals Publishes Prospectus for New Share Admission

Hemogenyx Pharmaceuticals has announced the publication of a Prospectus related to the admission of new ordinary shares to the London Stock Exchange. This move involves the conversion of convertible loan notes and the exercise of warrants, with trading expected to commence on 24 November 2025. This development is significant for Hemogenyx as it enhances their market presence and potentially impacts their financial standing by increasing the number of shares available for trading.